Government Briefs

Inside Out At NIH In their quest for the authority to pay higher salaries to attract top scientific talent, NIH officials are quick to claim that, since James Wyngaarden came from Duke University to become NIH director in 1982, they have been unable to fill any top administrative positions with outsiders. That streak came to an end in January with the appointment of James Snow, chairman of the department of otorhinolaryngology at the University of Pennsylvania School of Medicine, as the first d

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Inside Out At NIH
In their quest for the authority to pay higher salaries to attract top scientific talent, NIH officials are quick to claim that, since James Wyngaarden came from Duke University to become NIH director in 1982, they have been unable to fill any top administrative positions with outsiders. That streak came to an end in January with the appointment of James Snow, chairman of the department of otorhinolaryngology at the University of Pennsylvania School of Medicine, as the first director of the National Institute on Deafness and Other Communications Disorders. But Snow's appointment hasn't stopped NIH officials - most recently at last month's annual appropriations hearing in the House - from continuing to repeat their claim.

Meanwhile, as of March 23, NIH Acting Director William Raub had another vacancy to fill, that of deputy director for extramural research, resulting from the departure of neurologist Katherine Bick. Bick, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies